Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Pathology

Internal Medicine

Hematology

Rheumatology

Show all topics

DOI

10.1016/s0140-6736(18)31115-2

Other Formats

PDF